Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 +0.16%95 ROC (Joel Greenblatt) % is 13.12% as of Mar. 2026, which is 37% below its 10-year median of 20.86. GuruFocus rates BSP:RADL3 with a GF Score™ of 95/100 and a GF Value™ of R$30.02 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 667 Healthcare Providers & Services companies, Raia Drogasil ranks better than 63.27% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Raia Drogasil's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 13.12%.
The historical rank and industry rank for Raia Drogasil's ROC (Joel Greenblatt) % or its related term are showing as below:
BSP:RADL3'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.51 Med: 20.86 Max: 34.48
Current: 20.68
During the past 13 years, Raia Drogasil's highest ROC (Joel Greenblatt) % was 34.48%. The lowest was 12.51%. And the median was 20.86%.
BSP:RADL3's ROC (Joel Greenblatt) % is ranked better than 63.27% of 667
companies
in the Healthcare Providers & Services industry
Industry Median: 12.46
vs BSP:RADL3: 20.68
Raia Drogasil's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 9.60% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Raia Drogasil ROC (Joel Greenblatt) % Related Terms
Raia Drogasil ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 13.12% mean?
Raia Drogasil (BSP:RADL3) has a ROC (Joel Greenblatt) % of 13.12% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Raia Drogasil and its competitors. This is 37% below median its historical median of 20.86. Over the past decade, Raia Drogasil's ROC (Joel Greenblatt) % has ranged from 12.51 to 34.48. According to the industry distribution chart, Raia Drogasil ranks #245 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 36.7%.
Is Raia Drogasil's ROC (Joel Greenblatt) % too high?
Raia Drogasil's current ROC (Joel Greenblatt) % of 13.12% is 37% below median its 10-year median of 20.86. Over the past 10 years, this metric has ranged from a low of 12.51 to a high of 34.48. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.46. Raia Drogasil's value of 13.12% is 5.3% above this industry median. Based on the distribution chart, Raia Drogasil ranks #245 out of 667 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 95/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's ROC (Joel Greenblatt) % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #245 out of 667 companies for ROC (Joel Greenblatt) %. This puts Raia Drogasil in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 12.46. Raia Drogasil's value of 13.12% is 5.3% above this benchmark. Historically, Raia Drogasil's own ROC (Joel Greenblatt) % has ranged from 12.51 to 34.48 over the past decade. While the company's 10-year median is 20.86 vs. the industry median of 12.46, Raia Drogasil has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.46, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current ROC (Joel Greenblatt) % of 13.12% is 5.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current ROC (Joel Greenblatt) % is 13.12%, which is 37% below median its own 10-year median of 20.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$30.02, compared to a current price of R$18.55 — trading 38.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 13.12%, which is 37% below median its 10-year median of 20.86 and 5.3% above the Healthcare Providers & Services industry median of 12.46. Raia Drogasil's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current ROC (Joel Greenblatt) % is 13.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$18.55 is trading 38.2% below its estimated GF Value™ of R$30.02.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
ROC (Joel Greenblatt) %: 13.12% (37% below median its 10-year median of 20.86)
GF Value™: R$30.02 vs. price of R$18.55 (38.2% below fair value)
Industry Position: 5.3% above the Healthcare Providers & Services median (#245 of 667)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
95GF Score
Get the complete analysis for BSP:RADL3
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
